JP2021075579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021075579A5 JP2021075579A5 JP2021025180A JP2021025180A JP2021075579A5 JP 2021075579 A5 JP2021075579 A5 JP 2021075579A5 JP 2021025180 A JP2021025180 A JP 2021025180A JP 2021025180 A JP2021025180 A JP 2021025180A JP 2021075579 A5 JP2021075579 A5 JP 2021075579A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle
- composition according
- lyophilized
- complex
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000009027 Albumins Human genes 0.000 claims 6
- 108010088751 Albumins Proteins 0.000 claims 6
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066452A JP2022087255A (ja) | 2015-08-18 | 2022-04-13 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206770P | 2015-08-18 | 2015-08-18 | |
| US201562206771P | 2015-08-18 | 2015-08-18 | |
| US201562206772P | 2015-08-18 | 2015-08-18 | |
| US62/206,770 | 2015-08-18 | ||
| US62/206,771 | 2015-08-18 | ||
| US62/206,772 | 2015-08-18 | ||
| USPCT/US2015/054295 | 2015-10-06 | ||
| PCT/US2015/054295 WO2016057554A1 (en) | 2014-10-06 | 2015-10-06 | Carrier-antibody compositions and methods of making and using the same |
| USPCT/US2016/026270 | 2016-04-06 | ||
| PCT/US2016/026270 WO2017176265A1 (en) | 2016-04-06 | 2016-04-06 | Carrier-binding agent compositions and methods of making and using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506415A Division JP6921802B2 (ja) | 2015-08-18 | 2016-08-18 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066452A Division JP2022087255A (ja) | 2015-08-18 | 2022-04-13 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021075579A JP2021075579A (ja) | 2021-05-20 |
| JP2021075579A5 true JP2021075579A5 (enExample) | 2022-01-04 |
| JP7133050B2 JP7133050B2 (ja) | 2022-09-07 |
Family
ID=58051595
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506415A Active JP6921802B2 (ja) | 2015-08-18 | 2016-08-18 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2021025180A Active JP7133050B2 (ja) | 2015-08-18 | 2021-02-19 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2022066452A Withdrawn JP2022087255A (ja) | 2015-08-18 | 2022-04-13 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2022140647A Withdrawn JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506415A Active JP6921802B2 (ja) | 2015-08-18 | 2016-08-18 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066452A Withdrawn JP2022087255A (ja) | 2015-08-18 | 2022-04-13 | キャリア結合剤組成物およびそれを作製および使用する方法 |
| JP2022140647A Withdrawn JP2022164916A (ja) | 2015-08-18 | 2022-09-05 | キャリア結合剤組成物およびそれを作製および使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250170067A1 (enExample) |
| EP (1) | EP3337823A4 (enExample) |
| JP (4) | JP6921802B2 (enExample) |
| CN (2) | CN108290944B (enExample) |
| AU (1) | AU2016308337B2 (enExample) |
| CA (1) | CA2995384A1 (enExample) |
| IL (1) | IL256621A (enExample) |
| WO (1) | WO2017031368A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| AU2016308337B2 (en) * | 2015-08-18 | 2019-02-28 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| MX2019002473A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Métodos y composiciones para el direccionamiento de cánceres de células t. |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CA3035653A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| KR20220152263A (ko) * | 2020-03-11 | 2022-11-15 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체와 관련된 방법 및 조성물 |
| EP4208204A1 (en) | 2020-09-02 | 2023-07-12 | Mayo Foundation for Medical Education and Research | Antibody-nanoparticle complexes and methods for making and using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60146833A (ja) * | 1984-01-10 | 1985-08-02 | Green Cross Corp:The | モノクロ−ナル抗体製剤 |
| JPS6178731A (ja) * | 1985-05-20 | 1986-04-22 | Green Cross Corp:The | 加熱処理免疫グロブリン製剤 |
| EP0465513A1 (en) * | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| EA022201B1 (ru) * | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| WO2014055415A1 (en) * | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| NZ630239A (en) * | 2013-02-11 | 2017-08-25 | Abraxis Bioscience Llc | Methods of treating melanoma |
| KR102008859B1 (ko) * | 2014-10-06 | 2019-08-08 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 담체-항체 조성물 및 그의 제조 및 사용 방법 |
| AU2016308337B2 (en) | 2015-08-18 | 2019-02-28 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
-
2016
- 2016-08-18 AU AU2016308337A patent/AU2016308337B2/en not_active Ceased
- 2016-08-18 JP JP2018506415A patent/JP6921802B2/ja active Active
- 2016-08-18 CN CN201680047942.2A patent/CN108290944B/zh active Active
- 2016-08-18 CN CN202210483706.2A patent/CN114796130B/zh active Active
- 2016-08-18 EP EP16837869.3A patent/EP3337823A4/en active Pending
- 2016-08-18 CA CA2995384A patent/CA2995384A1/en active Pending
- 2016-08-18 WO PCT/US2016/047641 patent/WO2017031368A1/en not_active Ceased
-
2017
- 2017-12-27 IL IL256621A patent/IL256621A/en unknown
-
2021
- 2021-02-19 JP JP2021025180A patent/JP7133050B2/ja active Active
-
2022
- 2022-04-13 JP JP2022066452A patent/JP2022087255A/ja not_active Withdrawn
- 2022-09-05 JP JP2022140647A patent/JP2022164916A/ja not_active Withdrawn
-
2024
- 2024-07-26 US US18/785,952 patent/US20250170067A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021075579A5 (enExample) | ||
| JP2022087255A5 (enExample) | ||
| Barar et al. | Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer | |
| Gmeiner et al. | Nanotechnology for cancer treatment | |
| Tang et al. | The use of nanoparticulates to treat breast cancer | |
| Habibi et al. | Emerging methods in therapeutics using multifunctional nanoparticles | |
| Mohanty et al. | Receptor mediated tumor targeting: an emerging approach for cancer therapy | |
| Durymanov et al. | Current approaches for improving intratumoral accumulation and distribution of nanomedicines | |
| Kaminskas et al. | Targeting the lymphatics using dendritic polymers (dendrimers) | |
| CN108290944B (zh) | 载体结合剂组合物及其制备和使用方法 | |
| CN103655517B (zh) | 一种胶质瘤归巢肽介导的靶向纳米递药系统及其制备方法 | |
| CN102766215B (zh) | 一种具有协同靶向诊疗鼻咽癌功能的多肽和携带此多肽的纳米颗粒及其应用 | |
| US20190247357A1 (en) | Nanoparticle formulations and methods of making and using thereof | |
| Shukla et al. | Affinity of plant viral nanoparticle potato virus X (PVX) towards malignant B cells enables cancer drug delivery | |
| Safdari et al. | Use of single-chain antibody derivatives for targeted drug delivery | |
| Abdolvahab et al. | Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies | |
| Lin et al. | Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy | |
| CN107073132A (zh) | 载体‑抗体组合物及其制备和使用方法 | |
| Davoodi et al. | Internalizing RGD, a great motif for targeted peptide and protein delivery: a review article | |
| Ndong et al. | Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo | |
| Mehrizi et al. | An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review | |
| CN103169664A (zh) | 一种rgd肽修饰的双层载药纳米粒及其制备方法 | |
| Ruoslahti | Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier | |
| CN102172410A (zh) | 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法 | |
| C Baiu et al. | Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology |